New discoveries for an old drug: a review of recent olanzapine research

@article{Meftah2019NewDF,
  title={New discoveries for an old drug: a review of recent olanzapine research},
  author={Amir M. Meftah and Elizabeth Deckler and Leslie Citrome and Joshua T. Kantrowitz},
  journal={Postgraduate Medicine},
  year={2019},
  volume={132},
  pages={80 - 90}
}
ABSTRACT Objective: Based on a substantial literature, olanzapine appears to be one of the most efficacious antipsychotics marketed in the United States, with only clozapine clearly more advantageous. However, olanzapine is marred by an equally substantial literature demonstrating a metabolic burden of olanzapine, particularly for weight gain. With the publication of successful strategies to limit olanzapine induced weight gain, a reassessment of the clinical utility of olanzapine appears… Expand
An Evidence-Based Review of OLZ/SAM for Treatment of Adults with Schizophrenia or Bipolar I Disorder
TLDR
Clinical trial results support the use of OLZ/SAM as a new treatment option for patients with schizophrenia or BD-I and safety and tolerability findings from clinical studies indicate a similar safety profile to that of olanzapine, with the exception of less weight gain. Expand
NDT_A_313840 2885..2904
1Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY, USA; 2Alkermes, Inc., Waltham, MA, USA; 3Alkermes Pharma Ireland Limited, Dublin, Ireland Abstract:Expand
Olanzapine-Associated Rhabdomyolysis: A Case Report
TLDR
The presented case demonstrates that pharmacogenetic‐guided personalization of treatment may allow selecting the best medication and determining the right dosage, resulting in the reduced risk of adverse drug reactions and pharmacoresistance. Expand
Peripheral mechanisms of acute olanzapine induced metabolic dysfunction: A review of in vivo models and treatment approaches
TLDR
The purpose of this narrative review is to summarize work examining the peripheral mechanisms of acute olanzapine-induced related metabolic disturbances and discuss recent studies that have attempted to elucidate treatment approaches to mitigate AP-induced impairments in fuel metabolism. Expand
Agitation in schizophrenia: origins and evidence-based treatment.
  • L. Citrome
  • Medicine
  • Current opinion in psychiatry
  • 2020
TLDR
Comorbidities can contribute to agitation and can make an accurate differential diagnosis challenging and the ongoing development of rapidly acting novel formulations of antiagitation medications may facilitate clinical treatment by providing additional options. Expand
Targeting Serotonin 5-HT2A Receptors to Better Treat Schizophrenia: Rationale and Current Approaches
TLDR
The evidence for the role of the serotonin type 2A receptor (5-HT2AR) in schizophrenia is assessed and Food and Drug Administration (FDA)-approved and investigational 5- HT2AR-modulating compounds are reviewed. Expand
Specific Anti-hostility Effects of Atypical Antipsychotics in Persons with Schizophrenia: From Clozapine to Cariprazine.
LEARNING OBJECTIVE After participating in this activity, learners should be better able to:• Evaluate the anti-hostility effects of available atypical antipsychotic agents. ABSTRACT In addition toExpand
Olanzapine induced reproductive toxicity in male rats
TLDR
It was determined that reproductive toxic effects were induced in rats by OLZ administration, accompanied by alterations of the hormone levels and testicular oxidative stress. Expand
Lumateperone tosylate, A Selective and Concurrent Modulator of Serotonin, Dopamine, and Glutamate, in the Treatment of Schizophrenia.
TLDR
The background, evidence, and indications for the use of lumateperone tosylate in the treatment of schizophrenia are presented, and the most common adverse effects are shown to be mild such as somnolence, constipation, sedation, and fatigue. Expand
Mismatch negativity as an index of target engagement for excitation/inhibition-based treatment development: a double-blind, placebo-controlled, randomized, single-dose cross-over study of the serotonin type-3 receptor antagonist CVN058
TLDR
Results show MMN to be a sensitive target engagement biomarker for 5-HT3R, and support the potential utility of CVN058 in correcting the excitatory/inhibitory imbalance in schizophrenia. Expand
...
1
2
...

References

SHOWING 1-10 OF 101 REFERENCES
Olanzapine: review of safety 2008
TLDR
Olanzapine has a favorable profile in terms of extra-pyramidal side effects and is also relatively prolactin-sparing, and the effectiveness benefits may outweigh the risks, particularly in patients with low baseline risk for metabolic syndrome but monitoring for untoward metabolic effects is crucial. Expand
Olanzapine dosing above the licensed range is more efficacious than lower doses: fact or fiction?
TLDR
Dosing of olanzapine in clinical practice is higher than what has been established in the registration program for schizophrenia or bipolar disorder, and this is somewhat supported by double-blind, controlled clinical trial evidence. Expand
Olanzapine pamoate for the treatment of schizophrenia – a safety evaluation
TLDR
The safety profile of OLAI was similar to the well-known safety profiles of oral olanzapine, except for the risk of occurrence of post-injection delirium/sedation syndrome (PDSS). Expand
Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis.
TLDR
Existing data suggest that short term modest weight loss is possible with metformin in patients with olanzapine-induced weight gain, and current evidence is insufficient to support any particular pharmacological approach. Expand
Weight gain and antipsychotics: a drug safety review
TLDR
Recently published data still support the hierarchical ranking of SGAs already proposed in previous reviews, with clozapine and olanzapine as having the highest risk, followed by amisulpride, asenapine, iloperidone, paliperidone and quetiapine in the middle, and aripiprazole, lurasid one and ziprasidone with the lowest risk. Expand
Does formulation matter? A systematic review and meta-analysis of oral versus long-acting antipsychotic studies
TLDR
There is no robust evidence to support doctors in choosing LAI instead of oral formulations in order to obtain better tolerability and efficacy, and the effect estimate is close to the true effect. Expand
Mitigation of Olanzapine-Induced Weight Gain With Samidorphan, an Opioid Antagonist: A Randomized Double-Blind Phase 2 Study in Patients With Schizophrenia.
TLDR
It is suggested that samidorphan, an opioid antagonist, mitigates weight gain associated with olanzapine, and this study prospectively compared combination therapy of olanZapine plus either samidomorphan or placebo for the treatment of schizophrenia. Expand
Metformin for Weight Gain Associated with Second-Generation Antipsychotics in Children and Adolescents: A Systematic Review and Meta-Analysis
TLDR
Meta-analytical evidence shows that metformin might decrease weight in children/adolescents treated with SGAs but additional high-quality evidence is needed. Expand
Efficacy of olanzapine in comparison with clozapine for treatment-resistant schizophrenia: evidence from a systematic review and meta-analyses
TLDR
The results of this study suggest that clozapine is significantly more efficacious than olanzapine in improving positive and negative symptoms in TRS patients. Expand
Use of very-high-dose olanzapine in treatment-resistant schizophrenia
TLDR
A nuclear imaging study exploring brain occupancy by high-dose olanzapine, coupled with the present observational prospective study, may prove a relevant experimental paradigm for studying the pathophysiological mechanisms of resistant schizophrenia. Expand
...
1
2
3
4
5
...